Back to top

Immix Biopharma initiated with a Buy at BofA

BofA initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $27 price target Early data on NXC-201 shows about 95% complete response an...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Immix Biopharma, Inc. (IMMX)